Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. Inspire Medical Systems (INSP) closed the last trading session at $161.88, g ...

Inspire Medical Systems, Inc. (INSP) delivered an earnings per share (EPS) of 10 cents in first-quarter 2025 against the year-ago period’s loss of 34 cents per share and the Zacks Consensus Estimate of a loss of 23 cents. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)INSP’s Revenues in DetailInspire Medical registered revenues of $201.3 million in the first quarter, up 22.7% year over year. The figure beat the Zacks Consensus Estimate by 3.2%.Per management, the overall revenue gr ...

Company Performance - Inspire Medical Systems reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of a loss of $0.23 per share, and improved from a loss of $0.34 per share a year ago [1][2] - The earnings surprise for this quarter was 143.48%, following a previous quarter where the company reported earnings of $1.15 per share against an expectation of $0.74, resulting in a surprise of 55.41% [2] - The company achieved revenues of $201.32 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.20% and increasing from $164.01 million year-over-year [3] Market Outlook - Despite the positive earnings report, Inspire shares have declined approximately 13.8% since the beginning of the year, compared to a 3.3% decline in the S&P 500 [4] - The future performance of Inspire's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][5] - Current consensus EPS estimate for the upcoming quarter is $0.41 on revenues of $228.98 million, and for the current fiscal year, it is $2.16 on revenues of $949.61 million [8] Industry Context - Inspire operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable industry outlook [9] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into stock performance [6][7]

Inspire Medical Systems (INSP) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor RelationsTim Herbert - Chairman, President & CEORick Buchholz - CFOTravis Steed - Managing Director - Equity ResearchRichard Newitter - Managing DirectorChris Pasquale - Partner - Medical Devices & SuppliesAnthony Petrone - Managing DirectorJonathan Block - Managing DirectorBrett Gasaway - VP - Equity Research Conference Call Participants Danielle Antalffy - AnalystRober ...

Inspire Medical Systems (INSP) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor RelationsTim Herbert - Chairman, President & CEORick Buchholz - CFOTravis Steed - Managing Director - Equity ResearchRichard Newitter - Managing DirectorChris Pasquale - Partner - Medical Devices & SuppliesAnthony Petrone - Managing DirectorJonathan Block - Managing DirectorBrett Gasaway - VP - Equity Research Conference Call Participants Danielle Antalffy - AnalystRober ...

Inspire Medical Systems (INSP) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Speaker0 Good afternoon. My name is Dilem, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Inspire Medical Systems First Quarter twenty twenty five Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers remarks, there'll be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. Y ...

Inspire Medical Systems, Inc. May 2025 NYSE: INSP Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ''may,'' ''will,'' ''should,'' ''expect,'' ''plan,'' ''anticipate,'' ''could,'' "future," "outlook," ''intend,'' ''target,'' ''project,'' ''contemplate,'' ' ...

Financial Performance - Revenue for Q1 2025 was $201.3 million, a 22.7% increase from $164.0 million in Q1 2024[20] - Gross profit for Q1 2025 was $170.6 million, compared to $139.3 million in Q1 2024, reflecting a gross margin improvement[20] - Operating loss narrowed to $1.5 million in Q1 2025 from a loss of $15.2 million in Q1 2024[20] - Net income for Q1 2025 was $3.0 million, a significant recovery from a net loss of $10.0 million in Q1 2024[20] - Revenue for the three months ended March 31, 2025, was $201.3 million, a 22.7% increase from $164.0 million in the same period of 2024[125] - The operating loss for the three months ended March 31, 2025, was $1.5 million, significantly improved from a loss of $15.2 million in the same period of 2024[125] - The net income for the three months ended March 31, 2025, was $2.99 million, compared to a net loss of $10.0 million in the same period of 2024[132] - Gross profit for the three months ended March 31, 2025, was $170.6 million, with a gross margin of 84.7%, slightly down from 84.9% in the prior year[170][175] Cash and Assets - Cash and cash equivalents decreased to $53.9 million as of March 31, 2025, down from $150.2 million at the end of 2024[17] - Total assets decreased to $730.8 million as of March 31, 2025, from $808.4 million at the end of 2024[17] - Total liabilities decreased to $95.1 million as of March 31, 2025, from $118.7 million at the end of 2024[17] - As of March 31, 2025, total cash equivalents and investments amounted to $389.896 million, a decrease from $425.997 million as of December 31, 2024[42][44] - Cash, cash equivalents, and available-for-sale debt securities totaled $414.0 million as of March 31, 2025, a decrease of $102.5 million from $516.5 million as of December 31, 2024[182] Investments and Stock Repurchase - The company repurchased $75.0 million worth of common stock during Q1 2025[25] - The company has a share repurchase program authorized for up to $150.0 million, set to expire in August 2026[95] - An accelerated share repurchase agreement was entered into in November 2024, with a prepayment of $75.0 million for 409,043 shares at an average price of $190.29[96][97] - The company repurchased a total of 442,649 shares during the three months ended March 31, 2025, with an average price of $164.23 per share[214] Research and Development - Research and development expenses for Q1 2025 were $27.8 million, slightly down from $28.9 million in Q1 2024[20] - Research and development expenses are expected to increase as the company develops next generation versions of its Inspire system and expands clinical studies[165] - Research and development expenses include costs related to product development and clinical studies, with prelaunch inventory expensed unless regulatory approval is probable[71] Inventory and Expenses - Total inventories rose to $99,727,000 as of March 31, 2025, compared to $80,118,000 at the end of 2024, with finished goods increasing from $57,688,000 to $71,638,000[53] - Advertising expenses decreased from $25,600,000 in Q1 2024 to $20,900,000 in Q1 2025[76] - Total accrued expenses decreased from $49,814,000 at the end of 2024 to $34,333,000 as of March 31, 2025[62] - SG&A expenses rose by $18.7 million, or 14.9%, to $144.3 million for the three months ended March 31, 2025, primarily driven by a $17.4 million increase in compensation[177] Market and Operational Insights - Inspire Medical Systems continues to focus on expanding its innovative solutions for obstructive sleep apnea, with ongoing development of its proprietary Inspire system[27] - The company plans to fully launch its next generation Inspire system ("Inspire V") in the U.S. in 2025, following FDA approval in August 2024[151] - The company anticipates that some patients and physicians are delaying Inspire therapy until Inspire V is available, which may impact consolidated revenue until the full launch[152] - The company experienced supply disruptions in 2023, particularly related to polyurethane-based stimulation leads, which affected European revenue and consolidated revenue[147] - The global economic environment is facing challenges such as inflation and increased costs, which may lead customers to decrease or delay orders for the company's products[157] Tax and Income - The company recorded income tax expense of $1.2 million for the three months ended March 31, 2025, compared to $0.7 million for the same period in 2024[116] - The company had gross federal net operating loss carryforwards of $51.2 million as of December 31, 2024, which are no longer subject to expiration[117] Employee and Compensation - The company’s matching contributions to the employee retirement plan totaled $1.9 million for the three months ended March 31, 2025[94] - The total stock-based compensation expense recognized for the three months ended March 31, 2025, was $1.9 million, compared to $1.5 million for the same period in 2024[94] - The company has unearned stock-based compensation estimated to be expensed through 2028, amounting to $56.7 million for unvested stock options and $171.9 million for unvested RSUs[109][111] Accounting and Compliance - The company is evaluating the impact of recent accounting pronouncements, including ASU 2023-09 and ASU 2024-03, on its financial statement disclosures[86][87] - The company has not experienced material changes in its critical accounting policies and estimates from those described in its Annual Report[199]

Revenue Performance - Revenue for Q1 2025 was $201.3 million, a 23% increase from $164.0 million in Q1 2024[3] - U.S. revenue for the quarter was $193.6 million, reflecting a 24% increase compared to the prior year[3] - Full year 2025 revenue guidance is maintained at $940 million to $955 million, representing a growth of 17% to 19% over 2024[9] Profitability Metrics - Gross margin for Q1 2025 was 84.7%, slightly down from 84.9% in Q1 2024[4] - Operating loss improved to $1.5 million in Q1 2025, a 90% improvement from a loss of $15.2 million in the prior year[5] - Net income for Q1 2025 was $3.0 million, compared to a net loss of $10.0 million in Q1 2024[6] - Adjusted EBITDA for Q1 2025 was $33.2 million, up from $11.9 million in the same period last year[6] - The adjusted EBITDA margin improved to 16% in Q1 2025, compared to 7% in Q1 2024[29] - The net income margin improved to 1% in Q1 2025, compared to a negative margin of 6% in Q1 2024[29] Patient and Product Updates - The company surpassed 100,000 patients receiving Inspire therapy[2] - The Inspire V system is set for full launch in the U.S. this month[2] Financial Position - Total assets decreased from $808,383,000 on December 31, 2024, to $730,809,000 on March 31, 2025, representing a decline of approximately 9.6%[26] - Total current assets decreased from $630,806,000 at the end of 2024 to $571,679,000 by March 31, 2025, a reduction of about 9.4%[26] - Total liabilities decreased from $118,688,000 on December 31, 2024, to $95,066,000 on March 31, 2025, a decline of approximately 19.9%[26] - Cash and cash equivalents decreased significantly from $150,150,000 at the end of 2024 to $53,882,000 by March 31, 2025, a drop of approximately 64.1%[26] - Accounts payable decreased from $38,687,000 at the end of 2024 to $29,137,000 by March 31, 2025, a reduction of approximately 24.7%[26] Stock-Based Compensation - Stock-based compensation expense increased to $31,056,000 in Q1 2025, compared to $26,322,000 in Q1 2024, reflecting a rise of about 18.5%[28] Guidance Updates - Diluted net income per share guidance for 2025 is increased to between $2.20 to $2.30, up from the previous guidance of $2.10 to $2.20[9]

Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 ...